Oryzon Genomics announced the inclusion of the First Patient in the SAfety, Tolerability and Efficacy in an EPIGENETIC approach to treat Multiple Sclerosis, SATEEN, Phase IIA clinical trial with ORY-2001 in Multiple Sclerosis. The company further announced that it will present new data on ORY-2001 at the third annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018, which will take place February 1-3 at the Hilton San Diego Bayfront in San Diego, California. ORY-2001 is an orally administered, brain penetrant drug that selectively inhibits LSD1 and MAOB. The molecule has been shown to reduce cognitive impairment and neuroinflammation in preclinical models, and exerts neuroprotective effects. The drug has been tested in 6 month rat and 9 month dog GLP toxicology studies to enable long term Phase II studies. The safety and tolerability of ORY-2001 has been studied in a Phase I clinical trial with 106 young and elderly healthy volunteers, confirmed LSD1 target engagement and ORY-2001 brain penetration, and allowed to establish the doses for the Phase II dose finding studies in patients. In addition to the ongoing Phase IIA study with ORY-2001 in patients with Relapse-Remitting and Secondary Progressive multiple sclerosis (MS), the company aims to obtain authorization for a Phase IIA clinical trial in patients with Alzheimer's disease. LSD1 is an epigenetic modulator, which regulates histone methylation and modulates gene expression patterns. Epigenetic approaches to modify the progression of various neurodegenerative diseases, which focus on the production of changes in gene expression patterns in brain cells, have generated interest in the pharmaceutical industry.